This study is for adults with a type of lung cancer called Non-Small Cell Lung Cancer (NSCLC) that can be removed with surgery but did not completely go away after surgery. It tests if adding a new drug, sacituzumab tirumotecan, to an existing one, pembrolizumab, helps more than just using pembrolizumab alone. The goal is to see if the combination helps patients stay cancer-free longer. Pembrolizumab is already used to boost the immune system to fight cancer. Sacituzumab tirumotecan is a new drug being tested in this study.
- Participation Length: You'll need regular check-ups and have your progress monitored closely.
- Eligibility: You should have a specific type of lung cancer and meet other health criteria.
- Compensation and Risks: While there may be benefits, there could also be side effects from the treatment.
Before joining, talk to your doctor to understand the risks and benefits. This study is not for everyone, so make sure you meet the criteria and feel comfortable with the process.
How understandable was the trial content above?
Hard to understand
Easy to understand